Teva Pharmaceutical and Sanofi announced positive results from a Phase 2 study of duvakitug, a monoclonal antibody, for treating ulcerative colitis (UC) and Crohn's disease (CD). The study met its primary endpoints, with duvakitug demonstrating significant clinical remission and endoscopic response rates compared to placebo. The companies plan to progress to Phase 3 trials pending regulatory approvals.
Teva Pharmaceutical and Sanofi stocks were rising on Tuesday after the companies announced successful results of a phase 2 study involving the treatment of patients with ulcerative colitis and Crohn’s disease. The study investigated duvakitug, a human monoclonal antibody targeting, for the treatment of moderate-to-severe inflammatory bowel disease . UC and CD are the two main types of IBD .
“These unprecedented results show that duvakitug could represent the next frontier in treating ulcerative colitis and Crohn’s disease. If the magnitude of effect persists in the Phase 3 program, we believe we will have a differentiated medicine for IBD patients who are in urgent need of new options,” Houman Ashrafian, MD, PhD, executive vice president, head of R&D at Sanofi, said.
Pharmaceuticals Ulcerative Colitis Crohns Disease Clinical Trial IBD
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Stock Market Movers: Teva, Sanofi, Quantum Computing, SolarEdge, and Red CatThis article highlights the companies making significant moves in midday trading, including positive drug trial results, earnings reports, and contract wins.
Read more »
Teva, Sanofi Drug Shows Promise in Treating Crohn's, Ulcerative ColitisA study of a drug by Teva Pharmaceutical Industries and Sanofi showed promising results in treating Crohn's disease and ulcerative colitis, meeting key goals. The drug, duvakitug, demonstrated significant clinical remission rates in patients compared to a placebo.
Read more »
Teva and Sanofi's Dukavitug Shows Promise in Treating Ulcerative Colitis and Crohn's DiseaseTeva Pharmaceutical Industries and Sanofi announced positive results from a Phase 2 study of duvakitug, a human monoclonal antibody, for the treatment of moderate-to-severe inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). The study met its primary endpoints, demonstrating significant improvements in clinical remission and endoscopic response in patients treated with duvakitug compared to placebo.
Read more »
Gilead appoints Sanofi official Dietmar Berger as next chief medical officerGilead appoints Sanofi official Dietmar Berger as next chief medical officer
Read more »
Pharma giant Sanofi opens $595 million vaccine facility in Singapore to boost preparedness for potential pandemicsIt will contribute about 200 skilled jobs to the city-state, and will be fully operational by mid-2026.
Read more »
Sanofi Opens 595 Million Dollar 'Evolutive Vaccine Facility' in SingaporeSanofi has inaugurated a new facility in Singapore, known as Modulus, capable of producing different vaccines or treatments within days. This is part of a 900 million euro investment to develop two new EVFs globally.
Read more »